Citadel Advisors
CADX

Citadel Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Citadel Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,700
Closed -$43K – 8265
2013
Q4 		$43K Buy
4,700
+500
+12% +$3.61K ﹤0.01% 6134
2013
Q3 		$27K Sell
4,200
-3,900
-48% -$24.8K ﹤0.01% 6085
2013
Q2 		$55K Buy
+8,100
New +$56.4K ﹤0.01% 5618

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Citadel Advisors's CADX Position: Q1 2014 in Review

Citadel Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 134,667 shares — an estimated $1.22M sold.

Citadel Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $3.25M in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Citadel Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Citadel Advisors sold 134,667 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.22M.
  • Citadel Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Citadel Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $3.25M in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Citadel Advisors's 13F filing for Q1 2014, filed 15 May 2014.